Chief Financial Officer
Daniel Chen is the Chief Financial Officer of Kriya Therapeutics. Previously, Mr. Chen worked at Portola Pharmaceuticals for more than 10 years, most recently as Vice President of Business Planning and Corporate Strategy. In that role, he was responsible for leading the financial planning and analysis, treasure, purchasing, and strategic planning functions for the company. Prior to Portola, Mr. Chen held various roles in finance and commercial operations at Johnson & Johnson and Gilead Sciences.
Mr. Chen received his MBA from the University of Southern California and his undergraduate degree in Molecular Cell Biology from the University of California, Berkeley.